Matches in Wikidata for { <http://www.wikidata.org/entity/Q91815526> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q91815526 description "article scientifique publié en 2020" @default.
- Q91815526 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q91815526 description "im April 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91815526 description "scientific article published on 01 April 2020" @default.
- Q91815526 description "wetenschappelijk artikel" @default.
- Q91815526 description "наукова стаття, опублікована 1 квітня 2020" @default.
- Q91815526 name "Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials" @default.
- Q91815526 name "Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials" @default.
- Q91815526 type Item @default.
- Q91815526 label "Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials" @default.
- Q91815526 label "Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials" @default.
- Q91815526 prefLabel "Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials" @default.
- Q91815526 prefLabel "Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials" @default.
- Q91815526 P1433 Q91815526-C519B493-45E3-44EC-8D12-9EC2C0296DC1 @default.
- Q91815526 P1476 Q91815526-740B1CE6-87E6-4050-B945-9E95FFEA2AAC @default.
- Q91815526 P2093 Q91815526-10FB3DE8-9B1C-4904-9AB2-517F8AF6292B @default.
- Q91815526 P2093 Q91815526-21E2B05A-A049-4D87-8270-1F984D9B721C @default.
- Q91815526 P2093 Q91815526-6AEEDCA8-FA55-4E66-9E44-D8044692CC27 @default.
- Q91815526 P2093 Q91815526-6E88107B-970D-4935-BB6D-5C4E381BF5D9 @default.
- Q91815526 P2093 Q91815526-7D7DEE86-FD79-44D9-881A-760875E725F1 @default.
- Q91815526 P2093 Q91815526-8ED83B3E-0925-450B-B053-B116448828F8 @default.
- Q91815526 P31 Q91815526-59B49346-0DDB-4FA8-A494-B017DDBD36FE @default.
- Q91815526 P356 Q91815526-DA1E318A-226C-4DE3-82E9-CA1670923F4E @default.
- Q91815526 P433 Q91815526-AA497DA4-2BDD-4516-A6BB-A1AD2184CD7F @default.
- Q91815526 P478 Q91815526-8E0C0E87-1F5A-45C5-A86F-2714F63B7D30 @default.
- Q91815526 P50 Q91815526-65AD7C91-2F39-412C-B590-C1767236AC6B @default.
- Q91815526 P50 Q91815526-77CAFAB1-3D78-4121-B733-594A308E424A @default.
- Q91815526 P577 Q91815526-6B9F1537-0540-4C2B-A562-A116C00B4158 @default.
- Q91815526 P698 Q91815526-B88F831D-B80B-41B1-87E3-0DAE69304315 @default.
- Q91815526 P921 Q91815526-64BD1328-8CA9-4C1E-884F-C1D95906B468 @default.
- Q91815526 P932 Q91815526-0173E731-38B7-4454-BB60-3EB8D252CE39 @default.
- Q91815526 P356 ESMOOPEN-2019-000653 @default.
- Q91815526 P698 32276948 @default.
- Q91815526 P1433 Q53951848 @default.
- Q91815526 P1476 "Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials" @default.
- Q91815526 P2093 "Aya Kuchiba" @default.
- Q91815526 P2093 "Noboru Yamamoto" @default.
- Q91815526 P2093 "Ryunosuke Machida" @default.
- Q91815526 P2093 "Shigehisa Kitano" @default.
- Q91815526 P2093 "Takafumi Koyama" @default.
- Q91815526 P2093 "Toshio Shimizu" @default.
- Q91815526 P31 Q13442814 @default.
- Q91815526 P356 "10.1136/ESMOOPEN-2019-000653" @default.
- Q91815526 P433 "2" @default.
- Q91815526 P478 "5" @default.
- Q91815526 P50 Q59822314 @default.
- Q91815526 P50 Q86352626 @default.
- Q91815526 P577 "2020-04-01T00:00:00Z" @default.
- Q91815526 P698 "32276948" @default.
- Q91815526 P921 Q5452194 @default.
- Q91815526 P932 "7174012" @default.